Duchenne News

July 24, 2026
Satellos recently attended the International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy (July 7–11), where they presented six-month interim data from their ongoing TRAILHEAD clinical study evaluating SAT-3247 in...
July 22, 2026
  On July 20, Dyne Therapeutics announced that the FDA has accepted for review the Biologics License Application (BLA) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment...
July 14, 2026
On June 25, 2026, Avidity Biosciences, Inc. shared that they have submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of delpacibart zotadirsen (also known as...
July 10, 2026
The FDA has scheduled an Advisory Committee meeting for July 29, 2026 to review Deramiocel, Capricor’s investigational cell therapy for Duchenne muscular dystrophy. The meeting will be held in person with the...
July 3, 2026
On June 30, 2026, Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen)...
July 3, 2026
On June 29, 2026, Satellos Bioscience Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. Please read...
July 3, 2026
On June 26, 2026, Solid Biosciences, Inc. shared a Letter to the Duchenne Community containing updates on the INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE clinical studies, regulatory engagement, and...
July 3, 2026
On June 24, 2026, REGENXBIO Inc. announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. They also shared...
June 17, 2026
On June 10, 2026, Italfarmaco S.p.A. announced that Health Canada has accepted for review the New Drug Submission (NDS) for givinostat (Duvyzat®) for the treatment of Duchenne muscular dystrophy (DMD)....
June 4, 2026
On June 4, 2026, Avidity Biosciences shared an update on the planned AOC 1045 clinical trial for individuals with Duchenne muscular dystrophy amenable to exon 45 skipping (DMD45). To view...